In the latest trading session,, 3.08 million Novo Nordisk ADR (NYSE:NVO) shares changed hands as the company’s beta touched 0.66. With the company’s most recent per share price at $69.94 changing hands around $0.12 or 0.18% at last look, the market valuation stands at $235.44B. NVO’s current price is a discount, trading about -105.45% off its 52-week high of $143.69. The share price had its 52-week low at $57.00, which suggests the last value was 18.5% up since then. When we look at Novo Nordisk ADR’s average trading volume, we note the 10-day average is 8.65 million shares, with the 3-month average coming to 10.41 million.
Analysts gave the Novo Nordisk ADR (NVO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.03. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended NVO as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight.
Novo Nordisk ADR (NYSE:NVO) trade information
Instantly NVO is in green as seen in intraday trades today. With action 3.85%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -51.00%, with the 5-day performance at 3.85% in the green. However, in the 30-day time frame, Novo Nordisk ADR (NYSE:NVO) is -3.96% down. Looking at the short shares, we see there were 26.61 million shares sold at short interest cover period of 2.65 days.
The consensus price target for the stock as assigned by Wall Street analysts is 158, meaning bulls need an upside of 55.73% from its recent market value. According to analyst projections, NVO’s forecast low is 156 with 160 as the target high. To hit the forecast high, the stock’s price needs a -128.77% plunge from its current level, while the stock would need to soar -123.05% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.74%. The 2025 estimates are for Novo Nordisk ADR earnings to increase by 27.61%, but the outlook for the next 5-year period is at 18.96% per year.
NVO Dividends
Novo Nordisk ADR is expected to release its next quarterly earnings report on 2025-May-07. The 2.37% annual yield figure for the share gives it an annual dividend of 1.66. It is important to note, however, that the 2.37% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision. During the past 5 years, the average dividend yield was 1.46 per year.
Novo Nordisk ADR (NYSE:NVO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.01% of Novo Nordisk ADR shares while 9.85% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 9.85%. There are 9.85% institutions holding the Novo Nordisk ADR stock share, with JENNISON ASSOCIATES LLC the top institutional holder. As of 2024-06-30, the company held 0.476% of the shares, roughly 21.22 million NVO shares worth $3.03 billion.
FMR LLC holds the second largest percentage of outstanding shares, with 0.4373% or 19.49 million shares worth $2.78 billion as of 2024-06-30.
